Emi1抗体;Emi1 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Emi1 expression in HepG2 cell lysate.    

  
  

**Background of Emi1 Antibody**

Emi1 (Early Mitotic Inhibitor 1), also known as FBXO5. is a critical regulator of the cell cycle, primarily functioning as an inhibitor of the anaphase-promoting complex/cyclosome (APC/C). Discovered for its role in delaying APC/C activation until metaphase, Emi1 ensures proper progression through mitosis by preventing premature degradation of cyclin B and securin, proteins essential for sister chromatid separation. Structurally, Emi1 contains an F-box domain and a conserved inhibitory region (C-terminal loop) responsible for APC/C binding and suppression.

Dysregulation of Emi1 is linked to genomic instability and oncogenesis. Overexpression of Emi1 disrupts mitotic timing, leading to tetraploidy and chromosomal abnormalities, commonly observed in cancers such as breast, ovarian, and prostate tumors. Conversely, Emi1 depletion triggers unscheduled APC/C activation, resulting in mitotic collapse.

Emi1 antibodies are essential tools for studying cell cycle dynamics, protein interactions, and cancer mechanisms. They enable detection of Emi1 expression levels via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Researchers also utilize these antibodies to explore therapeutic strategies targeting Emi1-overexpressing cancers. Given its dual role as a checkpoint regulator and oncogenic driver, Emi1 remains a focal point in cell biology and oncology research.